A Scoring System Based on Nutritional and Inflammatory Parameters to Predict the Efficacy of First-Line Chemotherapy and Survival Outcomes for De Novo Metastatic Nasopharyngeal Carcinoma

References

• Tsao SW, Tsang CM, Lo KW. Epstein-barr virus infection and nasopharyngeal carcinoma. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 2017;372(1732):1732. doi:10.1098/rstb.2016.0270
   Web of Science ®Google Scholar
• Hanahan D, Weinberg R. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–e503. doi:10.1016/S1470-2045(14)70263-3
   PubMed Web of Science ®Google Scholar
• Shinko D, Diakos CI, Clarke SJ, Charles KA. Cancer-related systemic inflammation: the challenges and therapeutic opportunities for personalized medicine. Clin Pharmacol Ther. 2017;102(4):599–610. doi:10.1002/cpt.789
   PubMed Web of Science ®Google Scholar
• Putzu C, Cortinovis DL, Colonese F, et al. Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with nivolumab. Cancer Immunol Immunother. 2018;67(9):1349–1353. doi:10.1007/s00262-018-2182-4
   PubMed Web of Science ®Google Scholar
• Aziz MH, Sideras K, Aziz NA, et al. The systemic-immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels: a Retrospective Multicenter Cohort Study. Ann Surg. 2019;270(1):139–146. doi:10.1097/SLA.0000000000002660
   PubMed Web of Science ®Google Scholar
• Varkaris A, Katsiampoura A, Davis JS, et al. Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. Br J Cancer. 2019;120(3):340–345. doi:10.1038/s41416-018-0360-y
   PubMed Web of Science ®Google Scholar
• Galvano A, Peri M, Guarini AA, et al. Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score. Ther Adv Med Oncol. 2020;12:1758835920942378. doi:10.1177/1758835920942378
   Web of Science ®Google Scholar
• Banna GL, Signorelli D, Metro G, et al. Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab. Transl Lung Cancer Res. 2020;9(4):1533–1542. doi:10.21037/tlcr-19-583
   PubMed Web of Science ®Google Scholar
• Marinari E, Allard M, Gustave R, et al. Inflammation and lymphocyte infiltration are associated with shorter survival in patients with high-grade glioma. Oncoimmunology. 2020;9(1):1779990. doi:10.1080/2162402X.2020.1779990
   PubMed Web of Science ®Google Scholar
• Van Berckelaer C, Van Geyt M, Linders S, et al. A high neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated with a worse outcome in inflammatory breast cancer. Breast. 2020;53:212–220. doi:10.1016/j.breast.2020.08.006
   PubMed Web of Science ®Google Scholar
• Zengin M, Karahan İ. The role of cancer-related inflammation for prediction of poor survival in postmenopausal female patients with stage II/III colon cancer. Int Immunopharmacol. 2020;85:106624. doi:10.1016/j.intimp.2020.106624
   PubMed Web of Science ®Google Scholar
• Tu X, Ren J, Zhao Y. Prognostic value of prognostic nutritional index in nasopharyngeal carcinoma: a meta-analysis containing 4511 patients. Oral Oncol. 2020;110:104991. doi:10.1016/j.oraloncology.2020.104991
   PubMed Web of Science ®Google Scholar
• Miao J, Xiao W, Wang L, et al. The value of the Prognostic Nutritional Index (PNI) in predicting outcomes and guiding the treatment strategy of nasopharyngeal carcinoma (NPC) patients receiving intensity-modulated radiotherapy (IMRT) with or without chemotherapy. J Cancer Res Clin Oncol. 2017;143(7):1263–1273. doi:10.1007/s00432-017-2360-3
   PubMed Web of Science ®Google Scholar
• Peng H, Chen B, Tang L, et al. Prognostic value of nutritional risk screening 2002 scale in nasopharyngeal carcinoma: a large-scale cohort study. Cancer Sci. 2018;109(6):1909–1919. doi:10.1111/cas.13603
   PubMed Web of Science ®Google Scholar
• Deng J, He Y, Sun X, et al. Construction of a comprehensive nutritional index and its correlation with quality of life and survival in patients with nasopharyngeal carcinoma undergoing IMRT: a prospective study. Oral Oncol. 2019;98:62–68. doi:10.1016/j.oraloncology.2019.09.014
   PubMed Web of Science ®Google Scholar
• Kubo N, Sakurai K, Tamura T, et al. The impact of geriatric nutritional risk index on surgical outcomes after esophagectomy in patients with esophageal cancer. Esophagus. 2019;16(2):147–154. doi:10.1007/s10388-018-0644-6
   PubMed Web of Science ®Google Scholar
• Mao Y, Hao S, Zou C, Xie Z, Fu D. Controlling nutritional status score is superior to prognostic nutritional index score in predicting survival and complications in pancreatic ductal adenocarcinoma: a Chinese propensity score matching study. Br J Nutr. 2020;1–8. doi:10.1017/S0007114520004195
   Web of Science ®Google Scholar
• Lee S, Fujita K, Morishita T, et al. Prognostic utility of a geriatric nutritional risk index in combination with a comorbidity index in elderly patients with diffuse large B cell lymphoma. Br J Haematol. 2021;192(1):100–109.
   PubMed Web of Science ®Google Scholar
• National comprehensive cancer network head and neck cancers, version 2.June 9, 2020. Available from: http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed October 22, 2020.
   Google Scholar
• Li W-Z, Lv S-H, Liu G-Y, et al. Development of a prognostic model to identify the suitable definitive radiation therapy candidates in de novo metastatic nasopharyngeal carcinoma: a Real-World Study. Int J Radiat Oncol Biol Phys. 2021;109(1):120–130. doi:10.1016/j.ijrobp.2020.08.045
   PubMed Web of Science ®Google Scholar
• You R, Liu Y-P, Huang P-Y, et al. Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial. JAMA Oncol. 2020;6(9):1345. doi:10.1001/jamaoncol.2020.1808
   PubMed Web of Science ®Google Scholar
• Bouillanne O, Morineau G, Dupont C, et al. Geriatric nutritional risk index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr. 2005;82(4):777–783. doi:10.1093/ajcn/82.4.777
   PubMed Web of Science ®Google Scholar
• Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Sakamoto Y, Ishiguro M, Kitagawa G. Akaike information criterion statistics. Dordrecht Netherlands D Reidel. 1986;81(10.5555):26853.
   Google Scholar
• van Buuren S, Groothuis-Oudshoorn K. mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45(3):67%.
   PubMed Web of Science ®Google Scholar
• Chan O, Ngan R. Individualized treatment in stage IVC nasopharyngeal carcinoma. Oral Oncol. 2014;50(9):791–797. doi:10.1016/j.oraloncology.2014.01.004
   PubMed Web of Science ®Google Scholar
• Prawira A, Oosting SF, Chen TW, et al. Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review. Br J Cancer. 2017;117(12):1743–1752. doi:10.1038/bjc.2017.357
   PubMed Web of Science ®Google Scholar
• Chen Y, Chan A, Le Q, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–80. doi:10.1016/S0140-6736(19)30956-0
   PubMed Web of Science ®Google Scholar
• Fang W, Yang Y, Ma Y, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, Phase 1 trials. Lancet Oncol. 2018;19(10):1338–1350. doi:10.1016/S1470-2045(18)30495-9
   PubMed Web of Science ®Google Scholar
• Wang F, Wei X, Feng J, et al. Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02). J Clin Oncol. 2021;39(7):704–712.
   PubMed Web of Science ®Google Scholar
• Jin Y, Cai XY, Cai YC, et al. To build a prognostic score model containing indispensible tumour markers for metastatic nasopharyngeal carcinoma in an epidemic area. Eur J Cancer. 2012;48(6):882–888. doi:10.1016/j.ejca.2011.09.004
   PubMed Web of Science ®Google Scholar
• Jin Y, Ye X, Shao L, et al. Serum lactic dehydrogenase strongly predicts survival in metastatic nasopharyngeal carcinoma treated with palliative chemotherapy. Eur J Cancer. 2013;49(7):1619–1626. doi:10.1016/j.ejca.2012.11.032
   PubMed Web of Science ®Google Scholar
• Xia WX, Ye YF, Lu X, et al. The impact of baseline serum C-reactive protein and C-reactive protein kinetics on the prognosis of metastatic nasopharyngeal carcinoma patients treated with palliative chemotherapy. PLoS One. 2013;8(10):e76958. doi:10.1371/journal.pone.0076958
   PubMed Web of Science ®Google Scholar
• Choi Y, Kim JW, Nam KH, et al. Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer. Gastric Cancer. 2017;20(4):602–611. doi:10.1007/s10120-016-0642-0
   PubMed Web of Science ®Google Scholar
• Xia WX, Zhang HB, Shi JL, et al. A prognostic model predicts the risk of distant metastasis and death for patients with nasopharyngeal carcinoma based on pretreatment serum C-reactive protein and N-classification. Eur J Cancer. 2013;49(9):2152–2160. doi:10.1016/j.ejca.2013.03.003
   PubMed Web of Science ®Google Scholar
• Feng Y, Xiong Y, Qiao T, Li X, Jia L, Han Y. Lactate dehydrogenase A: a key player in carcinogenesis and potential target in cancer therapy. Cancer Med. 2018;7(12):6124–6136. doi:10.1002/cam4.1820
   PubMed Web of Science ®Google Scholar
• Zhang SL, He Y, Tam KY. Targeting cancer metabolism to develop human lactate dehydrogenase (hLDH)5 inhibitors. Drug Discov Today. 2018;23(7):1407–1415. doi:10.1016/j.drudis.2018.05.014
   PubMed Web of Science ®Google Scholar
• Liu -C-C, Ahearn JM. Chapter 10 - acute-phase proteins and inflammation: immunological and clinical implications. In: Lotze MT, Thomson AW, editors. Measuring Immunity. London: Academic Press; 2005:131–143.
   Google Scholar
• Cheung BM, Ong KL, Cheung RV, et al. Association between plasma alkaline phosphatase and C-reactive protein in Hong Kong Chinese. Clin Chem Lab Med. 2008;46(4):523–527. doi:10.1515/CCLM.2008.111
   PubMed Web of Science ®Google Scholar
• Namikawa T, Ishida N, Tsuda S, et al. Prognostic significance of serum alkaline phosphatase and lactate dehydrogenase levels in patients with unresectable advanced gastric cancer. Gastric Cancer. 2019;22(4):684–691. doi:10.1007/s10120-018-0897-8
   PubMed Web of Science ®Google Scholar
• Kojima Y, Sakurada T. Increase in alkaline phosphatase activity in the liver of mice bearing ehrlich ascites tumor. Cancer Res. 1976;36(1):23–27.
   PubMed Web of Science ®Google Scholar
• Rao SR, Snaith AE, Marino D, et al. Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer. Br J Cancer. 2017;116(2):227–236. doi:10.1038/bjc.2016.402
   PubMed Web of Science ®Google Scholar
• Whyte MP, Greenberg CR, Salman NJ, et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012;366(10):904–913. doi:10.1056/NEJMoa1106173
   PubMed Web of Science ®Google Scholar
• McMillan DC. The systemic inflammation-based glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–540. doi:10.1016/j.ctrv.2012.08.003
   PubMed Web of Science ®Google Scholar
• McMillan DC. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc. 2008;67(3):257–262. doi:10.1017/S0029665108007131
   PubMed Web of Science ®Google Scholar